United Therapeutics (UTHR) Reports In-Line Q4 EPS, Beats on Revenues
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 --0%
Revenue Growth %: -1.2%
Financial Fact:
Basic (in shares): 43.2M
Today's EPS Names:
FIZZ, LAKE, BNED, More
Revenue Growth %: -1.2%
Financial Fact:
Basic (in shares): 43.2M
Today's EPS Names:
FIZZ, LAKE, BNED, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.89, in-line with the analyst estimate of $3.89. Revenue for the quarter came in at $464.7 million versus the consensus estimate of $420.9 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- UBS Upgrades Eaton Corporation (ETN) to Buy
- AsiaStrategy adds Bitcoin-backed credit facility with Asian institution
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
